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ABSTRACT
The cancer stem cell (CSC) concept suggests that neoplastic clones are maintained 
exclusively by a rare group of cells possessed with stem cell properties. CSCs are 
characterized by features that include self-renewal, pluripotency and tumorigenicity, and 
are thought to be solely responsible for tumor recurrence and metastasis. A hierarchically 
organized CSC model is becoming increasingly evident for various types of cancer, 
including prostate cancer. The CD44 (+), CD133 (+) cell subpopulations were isolated 
from human prostate tumors which exhibit stem-like properties showing therapeutic-
resistance, capacity of self-renewal, and exact recapitulation of the original tumor in 
vivo. Thus, an important challenge is to find measures to eliminate these cancer stem 
cells, which will stop tumor growth and prevent disease-recurrence. However, knowledge 
about molecular features critical for the survival of prostate cancer stem cells (PCSC) is 
meager. Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591 
dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential 
role in the survival of PCSC. Interestingly, MK591 treatment decreases protein levels 
and inhibits transcriptional activities of Nanog and c-Myc. Since Nanog and c-Myc play 
important roles as stemness factors, our findings indicate that the 5-Lox activity plays a 
causal role in maintaining prostate cancer stemness via regulation of Nanog and c-Myc, 
and suggest that further exploration of 5-Lox-mediated signaling in PCSC may lead to 
development of novel, target-based, durable strategies to effectively block development 
and growth of prostate tumors, and prevent prostate cancer recurrence.
INTRODUCTION
The concept of cancer stem cell propounds that 
a small fraction of cells in tumors are capable of self-
renewal and to differentiate into various types of tumor 
cells, and are responsible for tumor formation, growth, 
progression and recurrence, while the majority of cells 
that make up bulk of the tumors are non-tumorigenic 
end cells [1–3]. The discovery of cancer stem cells has 
redesigned the concept of therapy of various types of 
cancer, because the “non-stem” cancer cells in a tumor 
can be destroyed by conventional therapies (e.g., radiation, 
surgery, chemotherapy), but these approaches are rarely 
successful in eliminating cancer stem cells [4–7]. Thus, 
the goal of current cancer therapy should be to develop 
strategies to destroy these resistant cancer cells endowed 
with stemness. Though our knowledge of CSCs and their 
micro-environmental niche is still a relatively new field, 
recent understanding about CSC’s dependence on critical 
survival and self-renewal signaling makes these regulatory 
pathways ready for development of novel therapeutic 
strategies. Cancer stem cells are a rare subset of cells 
in a tumor which are capable of eluding conventional 
treatment regimen and eventually regenerate tumors. 
Cancer stem cells can be extracted from a tumor based on 
molecular markers, and transplanted to form new tumors, 
from which the same tumor-propagating cells can again 
be isolated and re-transplanted [8]. This view puts forth 
the hypothesis that the vast majority of cells in a tumor 
undergo differentiation after originating from cancer 
stem cell and lose their self-renewal potential, and thus, 
cannot contribute to tumor formation and perpetuation. 
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The cancer stem cell concept has inspired many due to the 
potential of providing more durable and broadly applicable 
cancer cures by locating and targeting the tumor’s most 
notorious cells. However, many of the molecular features 
that regulate stemness and survival of cancer stem cells 
for their seemingly infinite and incessant proliferative 
capabilities are just now beginning to be appreciated. 
Cancer cells with stem-like properties have been 
identified in prostate tumors and characterized to be 
the population responsible for generating the diverse 
cell types within prostate tumors [8–12]. CSCs are also 
regarded as the seeds for therapeutic resistance, tumor 
recurrence and metastasis, and are recognized by a number 
of defined markers, such as they are positive for CD133 
and CD44, and express high levels of integrin alpha2beta1 
[13–17]. Recent identification of pluripotency markers 
(Nanog, c-Myc, Sox2) in prostate cancer stem cells and 
characterization of their unique molecular properties have 
opened up possibilities about how they can be targeted for 
more effective therapies. However, many of the stemness 
as well as tumorigenic markers are also present in other 
body cells, including normal stem cells [18, 19]. Thus, 
finding the root cause of therapeutic failures and targetable 
unique molecular properties need further characterization 
of prostate cancer stem cells. Most current therapies 
are directed to the majority of tumor mass consisting of 
fast-growing, differentiated cells but not the relatively 
slow-growing and resistant cancer stem cells which 
may underlie as a mechanism of why the cancer is not 
permanently eradicated with standard chemotherapy. The 
concept of CSC claims that cancers are driven by a set of 
stem cells in the same way as adult organs are maintained 
by dedicated tissue-specific stem cells [18]. Provoked by 
this new concept, a lot of excitement is now directed to 
go right after the root cause of the tumor and target those 
stem cells and eradicate cancer permanently. However, the 
destruction of prostate cancer stem cells should include 
measures that will selectively and systematically affect 
functions of critical molecular markers responsible for 
the maintenance, growth and differentiation of PCSCs. 
Thus, our approach was directed to examine the role of 
a newly-characterized mechanism, which plays important 
roles in the survival and proliferation of prostate cancer 
cells but not of normal cells [20–26], in the maintenance 
of stemness and survival of PCSC. 
Our strategy was to utilize an established, clinically-
relevant model of human PCSCs to interrogate the 
mechanisms of stem cell vulnerabilities and to find 
effective measures for controlling the population of PCSC 
which express both pluripotency markers (Nanog, c-Myc 
and Sox2) as well as the tumor-progenitor markers (CD44, 
CD133, and ALDH1) [27–29]. Especially for this work, 
our goal was to explore and characterize the role of a 
fatty acid metabolic pathway in human prostate tumor-
derived stem cells, to see whether it could be used as a 
mechanism-based target to control PCSC. Interestingly, 
most non-cancer parenchyma body cells, including 
normal stem cells, do not express 5-Lox under normal 
conditions, presumably because of hyper-methylation of 
the 5-Lox promoter [30, 31]. Moreover, 5-Lox knock-out 
mice have been developed which grow normally without 
any abnormalities and are fertile with normal litter size, 
supporting the concept that targeting 5-Lox may turn-
out to be a viable strategy to effectively eliminate PCSC 
without affecting most other normal body cells, and thus 
will not trigger overt toxicity to general health. We found 
that inhibition of 5-Lox downregulates Nanog, c-Myc and 
Sox2 and blocks sphere-formation, which suggests that 
the stemness characteristics in these cells are vulnerable to 
inhibition of 5-Lox activity. We also found that MK591, a 
specific 5-Lox inhibitor, dramatically reduces the viability 
and colony-forming abilities of PCSC, and induces c-JNK-
dependent apoptosis. These findings indicate that 5-Lox 
activity plays an important role in the survival of PCSC, 
and suggest that an effective, long-term curative therapy of 
prostate cancer is possible by targeting 5-Lox with suitable 
agents to eliminate PCSC via induction of apoptosis. 
RESULTS
Flow chart for isolation and characterization of 
prostate cancer stem cells from patient-derived 
tumors
A flow chart depicting the process of isolation of 
prostate cancer stem cells from patient prostate tumors 
is shown in Figure 1. These cells were rigorously tested 
for expression of stemness markers as well as for their 
high tumorigenicity by injecting 1000 cells per injection 
site in SCID (Severe Combined Immuno-Deficient) mice 
for quality control (Courtesy: Dr. Jay Sharma, Celprogen.
com, Torrance, CA). These cells were cultured on 
ECM (E36103-3PD)-coated plates in complete growth 
medium (M36103-30S) and incubated at 37°C in the 
incubator for expansion to get the desired numbers of 
cells for experiments. Positive markers for stemness 
and tumorigenicity of these cells were extensively 
characterized as a part of this study (Please see below).
5-lipoxygenase is heavily expressed in prostate 
cancer stem cells and plays a critical role in their 
survival
Earlier we reported that under standard culture 
condition prostate cancer cells express 5-Lox but non-
cancer cells do not, and that the 5-Lox activity plays a 
critical role in the survival of prostate cancer cells [20–26]. 
However, nothing was known about whether 5-Lox plays 
any role in the survival of prostate cancer stem cells. To 
explore a possible role of 5-Lox in prostate cancer stem 
cells, we observed that treatment with MK591, which 
specifically inhibits 5-Lox activity by binding with FLAP 
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or 5-lipoxygenase-activating protein [32–36], dramatically 
decreases the viability of PCSCs in a clear dose- and time-
dependent manner (Figure 2A–2E). Similar changes were 
also found when PCSCs were treated with 5-Lox shRNA, 
confirming a role of 5-Lox in the viability of these cells 
(Figure 2F–2H). Interestingly, MK591 does not affect the 
viability of normal cells or non-cancer stem cells under 
similar experimental conditions. To understand the basis 
of this differential sensitivity to 5-Lox inhibitors, we 
found that in contrast to prostate cancer stem cells, normal 
fibroblasts or the non-cancer stem cells do not express 
5-Lox. These findings suggest that specific inhibitors 
of 5-Lox may turn out to be useful to specifically target 
PCSCs without harming non-cancer body cells. Though 
we are intrigued by this novel and unexpected observation, 
downstream signaling mechanisms which mediate the 
regulation of prostate cancer stem cell survival by 5-Lox 
activity are yet to be fully understood. 
Inhibition of 5-Lox downregulates stemness in 
prostate cancer stem cells
Stemness in normal as well as cancer stem cells 
is maintained by a list of transcription factors such as, 
Nanog, c-Myc, Oct-4 and Sox-2 [13–17]. These stemness 
factors have also been well-characterized in PCSC 
and found to play important roles in the maintenance 
of stemness. However, details of their upstream and 
downstream regulations have yet to be fully characterized 
which may yield valuable information about manipulating 
them for long-term cancer control. Interestingly, we found 
that inhibition of 5-Lox dramatically downregulates the 
protein levels of Nanog, c-Myc and Sox2, indicating 
that the 5-Lox activity plays an important role in the 
regulation of stemness in PCSCs (Figure 3A). The 
decrease in protein level of Nanog was also found to 
be well-correlated with a decrease in its transcriptional 
activity (Figure 3B). Recently, we reported that inhibition 
of 5-Lox downregulates expression and function of 
c-Myc in prostate cancer cells involving inhibition of 
Stat3-mediated transcription [25, 26]. Moreover, we 
observed that inhibition of 5-Lox downregulates CD44, 
CD133, ALDH1 and ABCG2 which are characterized to 
be cancer stem cell- or tumorigenicity-markers in adult 
stem cells (Figure 3C). Though mechanistic details of 
the regulation of stemness factors by the activity of 
5-Lox in the biology of PCSC are yet to be understood, 
our findings show a possible molecular connection 
between metabolism of arachidonic acid through 5-Lox 
and the maintenance of stemness in prostate cancer stem 
cells. Formation of spheres in low-attachment plates is a 
standard characteristic of cancer stemness. Interestingly, 
we found that MK591 treatment dramatically inhibits the 
sphere-forming ability of PCSCs in a clear dose-dependent 
manner, suggesting that the 5-Lox activity is critical for 
maintaining stemness in these cells (Figure 3D). 
MK591 destabilizes mitochondria and induces 
apoptosis in prostate cancer stem cells
Based on previous observations of a critical role of 
5-Lox activity in prostate cancer stem cell survival, we 
wanted to explore downstream signaling mechanism(s) 
regulated by 5-Lox using MK591, a specific inhibitor 
of 5-Lox activity. We found that MK591 dramatically 
induces mitochondrial-membrane depolarization, which 
Figure 1: Flow chart of isolation and characterization of prostate cancer stem cells from human tumors. Human prostate 
tumor tissues were finely minced with scalpel and placed on ECM (E36103-3PD)-coated plates in complete growth medium (M36103-30S) 
and incubated at 37°C in the incubator for seven days. Then the tissues were lysed in protease enzyme solution to make single cell suspension 
and sorted by Flow Cytometry using indicated markers. Positive cells were cultured in non-differentiating complete growth medium for 
expansion of cells and finally tested for tumorigenicity using 1000 cells per injection site in SCID mice to develop subcutaneous tumors 
in ten days.
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is indicated by the loss of permeability barrier of 
mitotracker-red (Figure 4A, 4B). Externalization of 
phosphatidylserine is a hall-mark of apoptotic cell death. 
Thus, we wanted to examine whether prostate cancer stem 
cells also externalize phosphatidylserine when treated 
with MK591. We observed that prostate cancer stem 
cells show distinctly positive binding with annexin-V 
when treated with MK591, indicating externalization of 
phosphatidylserine to the cell surface (Figure 4C). We also 
observed that when prostate cancer stem cells were treated 
with MK591, these cells showed severe morphological 
alteration in a time-dependent manner. Characteristic 
caspase-mediated cleavage of poly-ADP-ribose 
polymerase (PARP) is another indicator of apoptosis, 
which was also observed in PCSC when treated with 
MK591 (Figure 4D), suggesting that inhibition of 5-Lox 
kills prostate cancer stem cells by triggering apoptosis. 
Inhibition of 5-Lox triggers apoptosis in 
prostate cancer stem cells via activation of c-Jun 
N-terminal kinase
Previously we have addressed the mechanism 
behind 5-Lox inhibition-induced apoptosis-triggering 
in prostate cancer cells, which revealed the involvement 
of c-Jun N-terminal Kinase and caspase-3 [22]. To 
explore the underlying mechanism in 5-Lox inhibition-
induced apoptosis in PCSC, we found that inhibition 
Figure 2: MK591 decreases viability of prostate cancer stem cells, but not of non-cancer cells or normal stem cells. 
(A), Human tumor-derived primary prostate cancer stem cells (Pri-PCSC) and DU145 cell line-derived cancer stem cells (DU-PCSC) were 
plated in 96 well tissue culture plates in complete growth medium supplemented with 10% serum. Normal human foreskin fibroblasts 
(HFF) and cord blood stem cells (CBSC) were also plated in serum-supplemented complete growth medium in parallel, Then, the cells were 
treated with varying doses of MK591, and the plates were further incubated for 72 hours at 37°C in the CO2 incubator. After incubation, cell 
viability was measured by MTS assay (Promega Corp, Wisconsin, MD). In (B), protein level of 5-lox was detected by Western blot. (C) 
and (D) show morphological alterations and culture density of normal HFF cells and PCSC as detected by microscopy. In (E) sensitivity of 
prostate cancer stem cells to different compounds was tested by MTS assay. Data presented as mean values of quadruplicate determination 
of each data point ± Standard Error. Note: While MK591 effectively killed PCSC, ibuprofen (a cyclooxygenase inhibitor) and cisplatin 
were found ineffective. (F–H) show morphology, level of 5-Lox protein, and viability of PCSC after treatment with shRNA against 5-Lox.
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of 5-Lox triggers rapid and robust activation of c-Jun 
N-terminal kinase in a dose- and time-dependent manner 
(Figure 5A, 5B). Further analysis revealed that the MK591 
treatment-induced apoptosis in PCSC is inhibited when 
the cells were pretreated with an inhibitor of c-JNK 
(SP600125), suggesting that 5-Lox inhibition-induced 
apoptosis in PCSCs is dependent on c-JNK activity 
(Figure 5C). Interestingly, cells treated with ibuprofen 
(a cyclooxygenase inhibitor) did not show any signs of 
apoptosis, suggesting specific effects of 5-Lox inhibition 
to induce apoptosis in prostate cancer stem cells.
Inhibition of 5-Lox induces apoptosis in prostate 
cancer stem cells via downregulation of PKCε, 
but without inhibition of Akt or ERK
How inhibition of 5-Lox triggers apoptosis in PCSC 
is an intriguing question. We addressed this by examining 
the effect of 5-Lox inhibition on well-characterized 
survival-regulating kinases. Previously, we reported 
that inhibition of 5-Lox induces apoptosis in prostate 
cancer cells without inhibition of the Akt, or ERK, but 
via a rapid decrease in the membrane-localization as well 
as enzymatic activity of PKCε [23, 37]. Involvement 
of PKCε has been reported to promote survival and 
decrease apoptosis in a variety of other cells [38–40]. 
To explore the kinase responsible for this mechanism of 
cell death in PCSC, we observed that inhibition of 5-Lox 
downregulates PKCε and phosphorylation of its substrates, 
but does not affect Akt or ERK in the same experimental 
conditions, suggesting that PKCε mediates the survival-
regulating effects of 5-Lox in PCSCs (Figure 6A). We also 
observed that inhibition of 5-Lox decreases the protein-
levels of survivin, cyclin D1, CDK4 and Bcl-xl, which are 
well-known regulators of cell survival and proliferation 
(Figure 6B). 
Figure 3: Inhibition of 5-Lox downregulates stemness in PCSC. In (A), PCSCs (3 × 105 per plate) were plated in complete 
growth medium supplemented with 10% serum in 60 mm diameter plates and allowed to grow for 48 hours. On the day of experiment, 
the spent culture medium was replaced with 2 ml fresh RPMI medium and the cells were treated with MK591 or ibuprofen at 37°C for 24 
hours as indicated. Control cells were treated with solvent only (0.2% DMSO). At the end of incubation period, cells were harvested and 
lysed. Protein levels in treated and untreated cells were detected by Western blot. (B) shows transcriptional activity of Nanog after treatment 
with varying doses of MK591 in Nanog-luciferase transfected PCSC. In (C), protein levels of adult stem cell markers are shown with or 
without treatment with MK591. (D) shows effect of MK591 on sphere formation by PCSC in ultra-low attachment plates in complete 
growth medium.
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Inhibition of 5-Lox blocks in vitro invasion as 
well as soft-agar colony formation by prostate 
cancer stem cells
We observed that treatment with sub-lethal doses 
of MK591 (10–20 μM) dramatically decrease the in vitro 
invasion of prostate cancer stem cells through extracellular 
matrix (Figure 7A, 7B). Moreover, we found that MK591 
dramatically affects the anchorage-independent colony-
forming ability of prostate cancer stem cells on soft-agar 
(Figure 7C, 7D). Note: Ibuprofen and cisplatin were 
used in parallel experiments and found to be ineffective 
to block colony formation by prostate cancer stem cells 
in the same culture conditions, suggesting that the effect 
of 5-Lox inhibition in these processes is highly selective. 
These in vitro experiments indicate that the activity of 
5-Lox is important for the maintenance of stemness and 
survival of PCSCs, and suggest that it is possible to inhibit 
the tumor-forming ability and therapeutic-resistance of 
PCSC by targeting 5-Lox with suitable agents (Figure 8).
DISCUSSION 
Our findings, for the first time, document that 5-Lox 
plays an essential role in the survival of prostate cancer 
stem cells, and that inhibition of 5-Lox kills these cells via 
induction of c-JNK-mediated apoptosis. Our observation 
of the massive induction of apoptosis in prostate cancer 
stem cells by specific inhibition of 5-Lox, opened 
up a unique possibility that both the progression and 
recurrence of prostate tumors can be vertically checked 
by eliminating these self-perpetuating and pluripotent 
cells by specific inhibitors of 5-Lox, such as MK591 
(Figures 1, 2). We found that the prostate cancer stem 
cell subpopulation overexpress stem cells markers such 
as Nanog, c-Myc and Sox2 which play important roles 
in cancer stemness signaling. Interestingly, protein levels 
of these factors and sphere-forming abilities of PCSCs 
are severely down-regulated when the cells are treated 
with 5-Lox inhibitors (Figure 3), which suggest that the 
expression and function of the stemness factors in prostate 
Figure 4: Inhibition of 5-Lox triggers mitochondrial permeability transition and induces apoptosis in PCSCs. In (A) and 
(B), PCSC and DU-PCSC (3 × 105 per plate) were plated in complete growth medium supplemented with 10% serum in 60 mm diameter 
plates and allowed to grow for 48 hours. On the day of experiment, the spent culture medium was replaced with 2 ml fresh RPMI medium 
and the cells were treated with MK591 as described in Figure 2. Then the cells were treated either with MK591 (30 μM) or ibuprofen 
(30 μM) for 24 hours. Then, the cells were stained with mitotracker-red for 60 minutes, counter-stained with Hoechst 33342 dye (blue), and 
observed under a fluorescent microscope (C). Membrane lipid asymmetry was detected by Annexin V binding. At the end of incubation 
period, cells in binding buffer were treated with FITC-labeled annexin-V and propidium iodide, and were observed under microscope at 
20×. In (D), at the end of incubation, cells were lysed and cleavage of PARP was detected by Western blot. 
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cancer stem cells are dependent on 5-Lox activity. An 
important role of Myc has been characterized in cancer 
stem cells, and the formation of spheres in low-attachment 
plates is a confirmative test for cancer-stemness [41–44]. 
Moreover, loss of 5-Lox activity triggers mitochondrial 
permeability-transition and induces apoptosis in these cells 
(Figure 4). It has been characterized that CSCs are highly 
prolific and considerably more resistant to conventional 
chemotherapeutics (such as, cisplatin, paclitaxel, 
adriamycin, and methotrexate) and radiation, meaning 
while common therapeutic procedures eliminate majority 
of actively proliferating cancer cells and yield bulk tumor 
shrinkage, the population of CSC survive because of 
their relatively slow growth and aberrant activation of 
signaling pathways. However, we observed that inhibition 
of 5-Lox commits these cells to undergo self-killing via 
phosphatidylserine externalization, and cleavage of PARP 
protein. Moreover, we observed that 5-Lox inhibition-
induced apoptosis in PCSC is mediated via activation of 
c-Jun N-terminal Kinase (Figure 5). Thus, we hope that 
agents such as MK591 may constitute valuable tools to 
exhaust the options of survival of these stubborn cells with 
virtually infinite self-renewing and incessant proliferating 
capabilities. 
Though the 5-Lox activity appears to play an 
important role in the survival of PCSC, downstream 
mechanism through which 5-Lox delivers survival 
signaling is not clearly understood. We found that 
inhibition of 5-Lox triggers apoptosis in PCSC without 
inhibition of PI3K-Akt, or MEK-ERK, two well-
characterized pro-survival mechanisms, but dramatically 
decreases the protein level of protein kinase C-epsilon 
(PKCε). These findings suggest that downstream 
mechanisms which mediate the survival-promoting effects 
of 5-Lox metabolites in PCSC involve the activity of 
PKCε, but not the more prevalent Akt or ERKs (Figure 6). 
Cancer stem cells possess the ability to disseminate and 
adhere to distant sites while retaining their stemness 
characteristics and thus regrow the tumor mass at new sites 
which eventually gives rise to metastatic lesions eventually 
Figure 5: MK591 treatment triggers activation of c-Jun N-terminal Kinase which plays a critical role in apoptosis. PCSCs 
(3 × 105 per plate) were plated in complete growth medium supplemented with 10% serum in 60 mm diameter plates and allowed to grow for 48 
hours. On the day of experiment, the spent culture medium was replaced with 2 ml fresh RPMI medium and the cells were treated with MK591 
as described in Figure 2 for 24 hours. In (A and B), dose and time-dependent changes in phosphorylation of c-JNK by MK591 treatment 
were detected by Western blots using phospho-specific antibodies. In (C), cells were pre-treated with c-JNK inhibitor (SP = SP600125) for 
30 minutes before treatment with MK591, and cell death was detected by staining with Annexin V-FITC as in Figure 4 above. 
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causing demise of the affected patients. Though CSCs 
constitute only a minor population in a tumor, they are 
extremely potent to generate the heterogeneous lineages 
of cancer cells that make up bulk of the tumor, signifying 
the importance of identifying robust agents which can 
broadly affect and eliminate the metastatic ability of CSC. 
Interestingly, we found that MK591 strongly inhibits the 
in vitro invasion and completely blocks the anchorage-
independent colony forming abilities of PCSCs on soft-
agar at sub-lethal doses (Figure 7). Previously we have 
demonstrated that in standard culture condition human 
prostate cancer cells continuously generate metabolites 
of 5-Lox from arachidonic acid which play an essential 
role in their survival [23–26]. Blocking 5-Lox activity 
triggers rapid apoptosis in prostate cancer cells which can 
be effectively prevented by exogenous active metabolites 
of 5-Lox, 5(S)-HETE and its dehydrogenated derivative 
5-oxoETE, documenting a pro-survival role of these 
metabolites in prostate cancer cells. The findings from 
our current in vitro experiments indicate that inhibition of 
5-Lox triggers apoptosis also in prostate cancer stem cells, 
suggesting that 5-Lox activity greatly contributes to the 
survival and apoptosis-resistance of prostate cancer stem 
cells by metabolic conversion of arachidonic acid, and 
signaling via a mechanism which is similar to that what 
exists also in differentiated prostate cancer cells. 
CSCs are a rare sub-population of cells present 
within the tumor, and are responsible for tumor-initiation, 
maintenance and tumor-recurrence. They possess 
unique biological properties, such as self-renewal and 
pluripotency. Moreover, they are thought to be more 
resistant to conventional chemotherapy and, as a result, 
are responsible for disease relapse. The core principle of 
cancer stem cells suggests that somewhere at the heart 
of a tumor there lies a handful of aberrant, genetically 
altered cells that are critical to maintain the malignant 
characteristics. This idea bears the potential to explain 
why tumors often regenerate long-time after even being 
destroyed by standard anticancer regimen. Moreover, 
it points to an alternative strategy for developing new 
generation of anticancer drugs, suggesting that these 
agents should be more selective towards the lethality of 
cancer stem cells and not to kill just any cells to shrink the 
tumor mass. Interestingly, cancer stem cells share many 
characteristics with normal stem cells, which include self-
perpetuation and differentiation to other cells, and with 
growing evidence that cancer stem cells indeed exist in a 
wide variety of tumor types, it is changing the landscape of 
tumor biology research. It is also  becoming increasingly 
relevant to understand the basic molecular mechanisms 
that regulate their self-renewal and differentiation because 
deregulation of genes involved in these pathways likely 
participate in basic characteristics of cancer viz tumor 
growth, recurrence and metastatic spread. The important 
question now is how to eliminate the cancer stem cells 
without killing normal stem cells because they are vital 
for maintaining tissue homeostasis? Since the inexorable 
growth of tumor is maintained by this rare group of stem/
progenitor cells within it, we can expect that the cancer 
stem cells, because of their unique biological features, 
may be more dependent on certain cellular processes than 
normal cells and thus, will be more vulnerable to some 
agents that block those processes. However, sorting out 
unique pathways that are critical for cancer stem cells, but 
not for non-tumor cells, though of utmost importance, is 
incredibly complex.
Figure 6: 5-Lox inhibition-induced apoptosis in prostate cancer stem cells involves inhibition of PKCε, but not Akt or 
ERK. PCS cells (3 × 105 per plate) were plated in complete growth medium supplemented with 10% serum in 60 mm diameter plates and 
allowed to grow for 48 hours. On the day of experiment, the spent culture medium was replaced with 2 ml fresh RPMI medium and the cells 
were treated either with MK591 (10–30 μM) or ibuprofen (30 μM) for 24 hours. Control cells were treated with vehicle only (0.2% DMSO). 
At the end of incubation, cells were harvested and proteins were separated in 12% SDS-PAGE. In (A), protein levels of PKC-epsilon and 
phosphorylations of Akt-pSer473, ERK-pThr202/Y204, Nanog-pThr200 and Stat3-pSer727, and in (B) protein levels of survivin, cyclin D1, CDK4 
and Bcl-xl were detected by Western blot. Data show a representative of three independent experiments with similar results.
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Figure 7: Effects of MK591 on in vitro invasion and soft-agar colony formation by PCSC. In (A), invasive capabilities of 
PCS cells were assayed using matrigel-coated transwell chambers as described in the “Methods” section. After incubation, cells were fixed 
and stained with crystal violet. Pictures were taken with a Leica microscope at ×200. (B) Shows quantitative measurements of the number 
of invaded cells with or without drug treatment. Results represent mean values of individual data point ± standard deviation (n = 3). ****p = < 
0.00005; *****p = < 0.000005. In (C), effects of MK591 on soft-agar colony formation by PCSC are shown. Cells were plated on soft-agar in 
complete medium and treated with drugs as indicated. After incubation for three weeks, cells were stained with crystal-violet and growing 
colonies were counted under microscope at ×150. Note: Dramatic inhibition was observed with MK591 treatment whereas the effects of 
ibuprofen and cisplatin were not distinguishable. In (D), results are shown quantitatively as mean values of each data point ± standard 
deviation (n = 3). ****p = < 0.00005.
Figure 8: Diagrammatic representation of the role of 5-lipoxygenase in the maintenance of stemness and survival of 
prostate cancer stem cells. Prostate cancer stem cells maintain stemness and tumorigenicity markers (Nanog, c-Myc, Sox2, CD44, 
CD133, ALDH1, ABCG2), and survival/proliferation markers (survivin, cyclin D1, CDK4, Bcl-xl) (Green), but undergoes c-JNK-mediated 
apoptosis when 5-lipoxygenase is inhibited (Red).
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The stem cell concept is enticing because of the 
potential it can provide to more durable and widespread 
cancer cures by identifying and attacking the tumor’s 
most notorious cells. Evidence is slowly accumulating to 
document that prostate cancer stem cells/tumor-initiating 
cells are key drivers in initiation and progression of prostate 
tumor. Therefore, successful therapy must eliminate these 
cells, which is hampered by their high inherent resistance 
to common therapeutic modalities. The discovery of cancer 
stem cells has led to formulation of new strategies in future 
therapy of prostate cancer. The so called “cancer normal 
cells” can be eliminated by conventional therapies (surgery, 
radiation, chemotherapy) relatively easily, though these are 
rarely successful in attacking “cancer stem cells.” To be 
successful, the new approach should therefore be to develop 
therapeutic approaches to destroy these cancer stem cells. 
Thus far, only a handful of studies have addressed the cancer 
stem cell killing potential of standard apoptosis-inducing 
therapies and the underlying molecular mechanisms of 
apoptosis-resistance in these cells. Though our knowledge 
of PCSCs and their microenvironment remains a relatively 
new field, our current observations of PCSC’s critical 
dependence upon 5-Lox activity for survival, as well as 
for the maintenance of self-renewal markers, make this 
regulatory mechanism ripe for developing experimental 
agents for effective management of prostate cancer. 
However, though it may be of high significance for 
development of durable prostate cancer therapy, whether 
5-Lox activity plays any role in the survival of prostate 
cancer stem cells was never addressed before. This report 
documents that inhibition of 5-Lox, triggers rapid and 
wide-spread apoptosis in prostate cancer stem cells via 
activation of c-Jun N-terminal Kinase, and that this process 
is associated with down-regulation of PKCε, but not Akt or 
ERKs as we observed in regular prostate cancer cells [23–
26, 37]. Moreover, inhibition of 5-Lox induces dramatic loss 
of stemness factors which are known to play important roles 
in self-regeneration and pluripotency of cancer stem cells. 
These findings indicate that 5-Lox activity may contribute 
to the survival and apoptosis-resistance of prostate cancer 
stem cells by metabolic conversion of arachidonic acid (an 
omega-6 polyunsaturated fatty acid, plentiful in our diets) 
and activation of PKCε, a transforming oncogene, and 
suggest that targeting 5-Lox with suitable agents may yield 
clues about effective, long-lasting therapy of prostate cancer 
and prevention of prostate cancer recurrence.
MATERIALS AND METHODS
Cell culture and reagents
Well-characterized human tumor-derived prostate 
cancer stem cells (CD133+, CD44+, ALDH1+, ABCG2+, 
Nanog+, c-Myc+) were purchased from Celprogen, 
Torrance, CA, USA [7] and were cultured in medium 
provided by the supplier. CD133+ human cord blood 
stem cells were isolated by Dr. N. Varma from fresh 
cord blood (provided by the Henry Ford Hospital) using 
antibody-coated magnetic beads (Miltenyi Biotech, San 
Diego, CA, USA). Human foreskin fibroblasts (HFF) 
and DU-145 prostate cancer cells were purchased from 
American Type Culture Collection (Manassas, VA, USA) 
and were grown in RPMI or DMEM medium 1640 
(Invitrogen, Carlsbad, CA, USA). All the media were 
supplemented with 10% FBS and antibiotics. Antibodies 
against Nanog, c-Myc and survivin were purchased 
from R and D Systems (Minneapolis, MN, USA), and 
antibodies against, Sox2, CD44, CD133, ABCG-2, 
cyclin D1, CDK4, and Bcl-xl were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Polyclonal 
antibodies against Akt, phospho-Akt (Ser473), phospho-
ERK1/2 (Thr202/Y204), phospho-JNK (Thr183/Y185), and 
phospho-Stat3 (Ser727), were purchased from Cell 
Signaling Technology (Danvers, MA, USA). Monoclonal 
anti-5-Lox antibody was purchased from BD Biosciences 
(Lexington, KY, USA). Anti-beta-actin antibody, ibuprofen 
and cisplatin were purchased from Sigma Chemical CO 
(St. Louis, MO, USA). MK591 was obtained as a generous 
gift from Dr. Robert N. Young (Merck-Frosst Centre for 
Therapeutic Research, Quebec, Canada).
Cell viability assay
Cell viability was measured by MTS/PES One 
Solution Cell Titer Assay (Promega Corp, Madison, WI, 
USA) as described before [23–26].
Microscopy
Cells (~3 × 105) were plated in complete growth 
medium supplemented with 10% FBS overnight onto 
60mm diameter tissue culture plates (Falcon) and allowed 
to grow for 48 hours. On the day of experiment, the spent 
culture medium was replaced with 2ml fresh RPMI medium 
and the cells were treated with inhibitors. Control cells were 
treated with solvent only (0.2% DMSO). Photographs were 
taken with a Nikon digital camera attached to a LEICA 
fluorescence microscope at ×400. Image acquisition and 
data processing were done with a Dell computer attached 
to the microscope using Q-Capture 7 software. 
Annexin-V binding
Cells (~3 × 105) were plated in complete medium and 
allowed to grow for 48 hours. On the day of experiment, 
the spent culture medium was replaced with fresh 2ml 
medium and the cells were treated with MK591 or 
ibuprofen for 24 hours at 37°C. Then the cells were treated 
with FITC-labeled annexin-V and propidium-iodide for 15 
minutes in the dark using an Annexin V-Binding Detection 
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Kit following a protocol supplied by the manufacturer 
(BD Biosciences). After washing, cells were photographed 
using a Nikon digital camera attached to a LEICA 
fluorescence-microscope at 20×. Image acquisition and 
data processing were done with a Dell computer attached 
to the microscope using Q-Capture 7 software.
Western blot
Cells (~3 × 105) were plated in 60mm diameter 
tissue culture plates and allowed to grow for 48 hours. 
The old medium was then replaced with 2ml fresh medium 
and the cells were treated with inhibitors. After treatment, 
cells were harvested, washed, and lysed in lysis buffer (50 
mM HEPES, pH 7.4, 150mM NaCl, 1mM EDTA, 1 mM 
orthovanadate, 10mM sodium pyrophosphate, 10 mM 
sodium fluoride, 1% NP-40, and a cocktail of protease 
inhibitors). Proteins were separated by 12% SDS–PAGE 
and transferred to nitrocellulose membranes. Membranes 
were blocked with 5% nonfat-milk solution and then 
blotted with appropriate primary antibodies followed 
by peroxidase-labeled secondary antibody. Bands were 
visualized by enhanced chemiluminescence (ECL) 
detection kit from Pierce Biotech (Rockford, IL, USA) 
and analyzed with a densitometer using Kodak imaging 
software. Unless otherwise mentioned, protein blots were 
analyzed in three independent experiments.
Luciferase assay
PCS cells were transfected with lentiviral Nanog-
luciferase constructs (> 90% cells transfected), expanded, 
and re-plated in 96 well culture plates in triplicates. Cells 
were then treated with MK591 or solvent only, and the 
luciferase activity was measured by a Luciferase Assay 
Kit from Promega Corporation (Madison, WI, USA) 
as we reported recently [25, 26]. Ibu (ibuprofen, a 
cyclooxygenase inhibitor) was used as negative control in 
parallel assays under the same culture conditions.
Invasion assay
Invasion chambers (BD Biosciences) were soaked 
with 50 μl DMEM medium for 30 minutes at room 
temperature in cell culture hood. Then, a 50 μl single cell 
suspension of ~40,000 PCSCs in DMEM was gently placed 
on top of the matrigel with or without drugs. These chambers 
were then placed in twenty four well cell culture plates (one 
in each well) containing 500 μl of DMEM medium plus 2% 
serum as attractant. The chambers were incubated overnight 
in the incubator at 37°C. On the next day, matrigels inside 
the chambers were carefully scraped out and the membranes 
were fixed in methanol, stained with crystal violet, mounted 
on glass slides and counted under microscope.
Soft-agar colony formation assay
Colony formation assays were performed in six 
well plates by placing ~5,000 Cells in 0.5 ml of 0.3% 
soft-agar on top of a 2 ml base layer of 0.6% agar. Plates 
were allowed to settle and then the wells were covered 
with 2 ml fresh medium containing 10% FBS with or 
without inhibitors. Plates were incubated at 37°C in the 
CO2 incubator for a maximum period of three weeks. Cell 
growth medium and inhibitors were exchanged every 
fourth day. At the end of incubation, cells were stained 
with 0.25% crystal violet and colonies were counted under 
a Leica microscope at ×150. 
Measurement of DNA degradation
Apoptosis was quantitatively measured by 
detecting degradation of nuclear DNA to nucleosomal 
fragments by sandwich-ELISA. Cells (~3 × 105) were 
plated in 60 mm dishes and allowed to grow for 48 hours. 
Cells were then treated either with the experimental 
agents or the solvent vehicle for varying periods of 
time up to 24 hours. At the end of incubation periods, 
cells were lysed and the degradation of chromatin 
DNA to nucleosomal fragments was measured by Cell 
Death Detection ELISAplus as described before [25, 26], 
following instructions supplied by the manufacturer 
(Roche, Indianapolis, IN, USA).
CONCLUSIONS
Our findings revealed a new mechanism in the 
regulation of stemness and survival of prostate cancer stem 
cells, which suggests that by blocking 5-lipoxygenase 
activity with suitable agents we can effectively eliminate 
prostate cancer’s most-resistant cells for development of a 
curative therapy of clinical prostate cancer and to prevent 
prostate cancer recurrence.
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